Thelansis

  Pulmonary alveolar proteinosis (PAP) is a rare disease characterised by alveolar accumulation of surfactant composed of proteins and lipids due to defective surfactant clearance by alveolar macrophages. Primary PAP is caused by reduced GM-CSF stimulation of alveolar macrophages, which reduces their ability to remove surfactant from alveoli and results in surfactant build-up and breathlessness. PAP prevalence has been reported from 3.7 to 40 cases per million, depending on the country. The incidence has been estimated to be 0.2 cases per million. Thelansis’s “Pulmonary Alveolar Proteinosis (PAP) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pulmonary Alveolar Proteinosis (PAP) ...